Small Molecule Drug Discovery Market, By Therapeutic Area (Oncology, Central Nervous System, Cardiovascular, Respiratory, Metabolic Disorders, Gastrointestinal, Others), By Process (Target ID/Validation, Hit Generation and Selection, Lead Identification,

Small Molecule Drug Discovery Market, By Therapeutic Area (Oncology, Central Nervous System, Cardiovascular, Respiratory, Metabolic Disorders, Gastrointestinal, Others), By Process (Target ID/Validation, Hit Generation and Selection, Lead Identification, Lead Optimization), By End User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic and Research Institutes, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Small molecule drugs have advantages over large molecule drugs such as higher oral bioavailability and better tissue penetration. These can be administered via various routes including oral, intravenous and others. Growing investment in R&D activities by pharmaceutical and biotech companies coupled with rising demand for generics can drive the market growth. However, high attrition rates during clinical trials can hamper the market growth. Several startups also leverage technologies such as artificial intelligence and machine learning to enhance the drug discovery process and reduce failure rates.

Market Dynamics:

Global small molecule drug discovery market growth is driven by rising pharmaceutical R&D spending, increasing demand for generic drugs, and growth of contract research and manufacturing services industries. However, high clinical failure rates of drug candidates and stringent regulations can hamper the market growth. Growing application of AI and machine learning in drug development offers new opportunities for the market players. Pharma companies are increasingly adopting such technologies to speed up the discovery process and optimize molecular designs. This can lower attrition rates. North America dominates the market currently, owing to presence of major players and high healthcare expenditure. Asia Pacific is anticipated to emerge as the fastest growing market in the near future.

Key features of the study:

• This report provides in-depth analysis of the global small molecule drug discovery market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global small molecule drug discovery market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer, Bristol-Myers Squibb Company, Merck, Agilent Technologies, AstraZeneca, Boehringer Ingelheim, Charles River Laboratories
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global small molecule drug discovery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global small molecule drug discovery market

Detailed Segmentation-

• Therapeutic Area Insights (Revenue, USD, 2019 - 2031)
• Oncology
• Central Nervous System
• Cardiovascular
• Respiratory
• Metabolic Disorders
• Gastrointestinal
• Others
• Process Insights (Revenue, USD, 2019 - 2031)
• Target ID/Validation
• Hit Generation and Selection
• Lead Identification
• Lead Optimization
• End User Insights (Revenue, USD, 2019 - 2031)
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutes
• Others
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Pfizer Inc.
• Merck & Co., Inc.
• Novartis AG
• Johnson & Johnson
• AstraZeneca PLC
• GlaxoSmithKline plc
• Bristol Myers Squibb
• Eli Lilly and Company
• Gilead Sciences, Inc.
• Teva Pharmaceuticals
• Boehringer Ingelheim GmbH
• Thermo Fisher Scientific Inc.
• Charles River Laboratories
• Labcorp Drug Development
• Agilent Technologies Inc.
• ICON Plc
• Eurofins Discovery
• Immunocure Inc.
• Acacia Pharma Group
• 4SC AG